251468-84-5

Basic information

• Product Name: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-bromophenyl)-
• Synonyms: 1-(4-Bromo-phenyl)-pyrimidine-2,4,6-trione
• CAS NO: 251468-84-5
• Molecular Formula: C10H7BrN2O3
• Molecular Weight: 283.081
• Mol File: 251468-84-5.mol
• Article Data: 4

Chemical Properties

• Density: 1.732±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-bromophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-bromophenyl)-(251468-84-5)
• EPA Substance Registry System: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-bromophenyl)-(251468-84-5)

Safety Data

• Hazardous Substances Data: 251468-84-5(Hazardous Substances Data)

Usage

Description

2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-bromophenyl)is a chemical compound characterized by its unique molecular structure, which features a pyrimidinetrione core with a 4-bromophenyl group attached. This structure endows the compound with specific properties that make it suitable for various applications in different industries.

Uses

Used in Pharmaceutical Industry:
2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(4-bromophenyl)is used as a key intermediate in the synthesis of 5-arylidene barbiturates, which are potent, selective, and reversible LSD1 inhibitors. These inhibitors play a crucial role in the treatment of acute promyelocytic leukemia, a rare and aggressive form of blood cancer. The compound's ability to optimize the development of these inhibitors makes it a valuable asset in the fight against this life-threatening disease.

Upstream product

• 106-40-1 4-bromo-aniline 
• 1967-25-5 4-bromophenylurea 
• 105-53-3 diethyl malonate 

Downstream Products

• 1070801-91-0 (Z)-1-(4-bromophenyl)-5-{[(2-chlorophenyl)amino](mercapto)methylidene}pyrimidine-2,4,6(1H,3H,5H)-trione 
• 1070801-89-6 (Z)-1-(4-bromophenyl)-5-{[(3,5-difluorophenyl)amino](mercapto)methylidene}pyrimidine-2,4,6(1H,3H,5H)-trione 

Relevant articles and documents

Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia

Histone lysine specific demethylase 1 (LSD1) is overexpressed in diverse hematologic disorders and recognized as a promising target for blood medicines. In this study, molecular docking-based virtual screening united with bioevaluation was utilized to identify novel skeleton of 5-arylidene barbiturate as small-molecule inhibitors of LSD1. Among the synthesized derivatives, 12a exhibited reversible and potent inhibition (IC50 = 0.41 μM) and high selectivity over the MAO-A and MAO-B. Notably, 12a strongly induced differentiation effect on acute promyelocytic leukemia NB4 cell line and distinctly escalated the methylation level on histone 3 lysine 4 (H3K4). Our findings indicate that 5-arylidene barbiturate may represent a new skeleton of LSD1 inhibitors and 12a deserve as a promising agent for the further research.

Barbiturate compound, preparing method and application thereof

The invention belongs to the field of medicinal chemistry, and discloses a barbiturate compound, a preparing method and application thereof. Specifically, the invention relates to the compound as shown in formula I, and a medicinal usage thereof as a selective LSD1 reversible inhibitor, particular to the application in preparing of antitumor medicine. A test shows that the compound in formula I can efficiently reversibly inhibit LSD1 activity, and has a weak inhibition action for homologous proteins MAO-A and MAO-B, can intensively induce differentiation of leukemia cell NB4 and obviously enhance the methylation level of primers H3K4me1 and H3K4me2 of the LSD1.